{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:24:20Z","timestamp":1790843060870,"version":"4.1.0"},"reference-count":45,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec id=\"S1092852917000025_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>This post-hoc analysis assessed rates of symptomatic and functional remission, as well as recovery (combination of symptomatic and functional remission), in patients treated with lurasidone for major depressive disorder (MDD) associated with subthreshold hypomanic symptoms (mixed features).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000025_abs2\" sec-type=\"general\"><jats:title>Method<\/jats:title><jats:p>Patients with MDD plus two or three manic symptoms (defined as per the DSM\u20135 mixed-features specifier) were randomly assigned to flexible-dose lurasidone 20\u201360 mg\/day (<jats:italic>n<\/jats:italic>=109) or placebo (<jats:italic>n<\/jats:italic>=100) for 6 weeks, followed by a 3-month open-label, flexible-dose extension study for U.S. sites only (<jats:italic>n<\/jats:italic>=48). Cross-sectional recovery was defined as the presence of both symptomatic remission (Montgomery\u2013\u00c5sberg Depression Rating Scale score \u2264 12) and functional remission (all Sheehan Disability Scale [SDS] domain scores \u22643) at week 6, and at both months 1 and 3 of the extension study (\u201csustained recovery\u201d).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000025_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>A significantly higher proportion of lurasidone-treated patients (31.3%) achieved recovery (assessed cross-sectionally) compared to placebo (12.2%, <jats:italic>p<\/jats:italic>=0.002) at week 6. The number of manic symptoms at baseline moderated the effect size for attaining cross-sectional recovery for lurasidone treatment (vs. placebo) (<jats:italic>p<\/jats:italic>=0.028). Sustained recovery rates were higher in patients initially treated with lurasidone (20.8%) versus placebo (12.5%).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000025_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>In this post-hoc analysis of a placebo-controlled study with open-label extension that involved patients with MDD and mixed features, lurasidone was found to significantly improve the rate of recovery at 6 weeks (vs. placebo) that was sustained at month 3 of the extension study. The presence of two (as opposed to three) manic symptoms moderated recovery at the acute study endpoint.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852917000025","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T09:08:56Z","timestamp":1488877736000},"page":"220-227","source":"Crossref","is-referenced-by-count":11,"title":["Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension"],"prefix":"10.1017","volume":"22","author":[{"given":"Joseph F.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Ng-Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chia","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"key":"S1092852917000025_ref43","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.10.1645"},{"key":"S1092852917000025_ref34","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.108357"},{"key":"S1092852917000025_ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2010.09071011"},{"key":"S1092852917000025_ref35","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f2b4d6"},{"key":"S1092852917000025_ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2011.00903.x"},{"key":"S1092852917000025_ref42","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291710001911"},{"key":"S1092852917000025_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.158"},{"key":"S1092852917000025_ref36","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802293643"},{"key":"S1092852917000025_ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00726.x"},{"key":"S1092852917000025_ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2011.00957.x"},{"key":"S1092852917000025_ref20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15060770"},{"key":"S1092852917000025_ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01324.x"},{"key":"S1092852917000025_ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-009-1626-0"},{"key":"S1092852917000025_ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-016-0049-1"},{"key":"S1092852917000025_ref37","first-page":"298","article-title":"Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan Disability Scale, pooled analysis of data from six randomized, double-blind, placebo-controlled clinical trials","volume":"27","author":"Mancini","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"S1092852917000025_ref9","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09092"},{"key":"S1092852917000025_ref28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.05122032"},{"key":"S1092852917000025_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00332-4"},{"key":"S1092852917000025_ref14","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"S1092852917000025_ref15","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"S1092852917000025_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-013-0393-4"},{"key":"S1092852917000025_ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.87"},{"key":"S1092852917000025_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2005.07.024"},{"key":"S1092852917000025_ref25","volume-title":"Structured Clinical Interview for DSM\u2013IV\u2013TR Axis I Disorders, Clinical Trials Version (SCID\u2013CT)","author":"First","year":"2007"},{"key":"S1092852917000025_ref27","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199606003-00015"},{"key":"S1092852917000025_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-8343(00)00072-4"},{"key":"S1092852917000025_ref40","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852915000826"},{"key":"S1092852917000025_ref30","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m08049"},{"key":"S1092852917000025_ref38","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799001841"},{"key":"S1092852917000025_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12338"},{"key":"S1092852917000025_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.179"},{"key":"S1092852917000025_ref31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4088\/JCP.15m09918","article-title":"A new empirical definition of major depressive episode recovery and its positive impact on future course of illness","volume":"77","author":"Judd","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"S1092852917000025_ref32","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"S1092852917000025_ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0073-y"},{"key":"S1092852917000025_ref41","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09548"},{"key":"S1092852917000025_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.01.023"},{"key":"S1092852917000025_ref29","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770300115013"},{"key":"S1092852917000025_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.09.016"},{"key":"S1092852917000025_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.07.033"},{"key":"S1092852917000025_ref26","first-page":"218","volume-title":"Early Clinical Drug Evaluation Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S1092852917000025_ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064135"},{"key":"S1092852917000025_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.09.026"},{"key":"S1092852917000025_ref18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070984"},{"key":"S1092852917000025_ref24","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S1092852917000025_ref19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070985"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852917000025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T01:52:43Z","timestamp":1555552363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852917000025\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1092852917000025"],"URL":"https:\/\/doi.org\/10.1017\/s1092852917000025","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,7]]}}}